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Abstract
Objective Animal studies have indicated that perflu-
oroalkylated substances (PFAS) increase mammary fi-
broadenomas. A recent case–control study in Greenlandic
Inuit women showed an association between the PFAS
serum levels and breast cancer (BC) risk. The present study
evaluates the association between serum levels of PFAS in
pregnant Danish women and the risk of premenopausal BC
during a follow-up period of 10–15 years using prospec-
tively collected exposure data during the pregnancy.
Methods Questionnaire and blood samples were taken
during 1996–2002 and at the end of follow-up, all 250 BC
cases and 233 frequency-matched controls were chosen for
further analyses. Serum levels of ten perfluorocarboxylated
acids, five perfluorosulfonated acids, and one sulfonamide
(perflurooctane-sulfonamide, PFOSA) were determined by
liquid chromatography-tandem mass spectrometry with
electrospray ionization in negative mode. Computer-assis-
ted telephone interviews taken during pregnancy provided
data on potential confounders.
Results Weak positive and negative insignificant associa-
tions were found between BC risk and levels of perfluoro-
octane sulfonamide (PFOSA) and perfluorohexanesulfonate
(PFHxS), respectively. Grouped into quintile, the BC cases
had a significant positive association with PFOSA at the
highest quintiles and a negatively association for PFHxS.
Sensitivity analyses excluding uncertain cases caused
stronger data for PFOSA and weaker for PFHxS. No fur-
ther significant associations were observed.
Conclusions This study does not provide convincing
evidence for a causal link between PFAS exposures and
premenopausal BC risks 10–15 years later.
Keywords Breast cancer  Perfluoroalkyl substances 
Premenopausal Danish women  Prospective collected data
Introduction
The incidence of breast cancer (BC) has been increasing
worldwide in the last decades and BC accounts for 23 % of
the total cancer cases and 14 % of cancer deaths among
females [1]. BC incidence in Denmark has increased in the
last six decades [2] to reach 144 cases per 100,000 woman
year. Approximately one in ten women will develop BC at
some time in their lives [3]. In spite of intense research, the
reasons for the increasing BC incidence are only partly
known. Research should focus on exposures that have
increased over time such as persistent organic pollutants
(POPs), e.g., perfluoroalkylated substances (PFAS).
BRCA1 and BRCA2 gene mutations account for about
5–10 % of all breast cancers [4]. In addition to age, known
risk factors include earlier menarche, later menopause, older
age at first childbirth, parity, and short duration of breast
feeding, but they explain only a small part of the increasing
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BC trend. Changes in diet (e.g., high intake of fat), post-
menopausal obesity, and alcohol consumption, smoking, and
low physical activity may also play a role [5–7].
The risk of BC increases with earlier menarche and later
menopause, indicating that breast tissue is sensitive to pro-
longed endogenous steroid exposure, as seen with exogenous
hormone replacement therapy (HRT). Still, all established
BC risk factors, including genetic inheritance and factors
contributing to lifelong exposure to active estrogens,
endogenous and synthetic hormones, can only explain
\40 % of all cases [8]. For this reason, we need to identify
other potential risk factors. In this study we focus on PFAS, a
large group of chemicals used since the 1950s in different
industrial and commercial applications (e.g., Teflon, carpets,
furniture, foodstuff packing, etc.). These fluorinated chem-
icals were until recently considered metabolically inert and
nontoxic [9]. Available evidence suggests that the transfor-
mation or biodegradation of precursor perfluorinated
chemicals occurs via both abiotic and biotic degradation
pathways where perfluorooctane sulfonate (PFOS) and per-
fluorooctanoic acid (PFOA) are typical final degradation
products [10, 11]. In 2001, it was discovered that PFAS are
accumulating in the environment, and in animal and human
tissues with a global distribution [10–12].
The PFAS bind to blood proteins and are stored mainly
in liver, kidney, and bile excretions [13]. Humans are
exposed to PFAS through occupational settings, environ-
mental exposures, and/or through contact with consumer
goods (e.g., diet, air, water, food, and household dust)
where PFAS have been found.
The PFAS include the perfluorocarboxylated acids
(PFCAs) and perfluorosulfonated acids (PFSAs), which
include PFOA and PFOS. PFOS and PFOA are the two
most studied PFAS because they are found at relative
higher levels compared to other PFAS and laboratory
procedures in the past were not sensitive enough to identify
lower concentrations. Recently, PFOS has been added to
Annex B of the Stockholm Convention on POPs [14]. The
biological effects of PFAS have been studied in more detail
mainly in rodents, and limited data are available for other
species and humans [13, 15]. Studies in animals have
documented an array of toxicological outcomes including
liver hypertrophy and tumors [16], thyroid hormone alter-
ations, decreased serum cholesterol and glucose, develop-
mental toxicity, immunotoxicity, and carcinogenic potency
[17, 18]. Animal and in vitro studies have also suggested
that PFAS may have potential geno- and neuro-toxic
effects [19, 20]. The US EPA has proposed PFOA to be
classified as a rodent carcinogen with relevance to humans
[21]. A rat study [22] reported a statistically significant
increase in mammary fibroadenomas and Leydig cell ade-
nomas, whereas two other rat studies did not find increased
incidence of mammary-gland neoplasms upon a 2-year
chronic dietary administration of ammonium perflu-
orooctanoate [23, 24]. Thus, conflicting data for PFOA
exposure in rats are reported. In mice, however, gestational
exposure to PFOA compared to non-exposed controls was
found associated with altered mammary-gland develop-
ment in dams and female offspring, and a significant
reduction in mammary differentiation among exposed
dams was evident also affecting the epithelial involution
and altered milk protein gene expression [25]. Because of
these data, the US EPA Science Advisory Board recom-
mended to reconsider the possible impact of PFOA on
mammary tissues [21, 26].
An association between PFAS serum levels and the risk
of BC was recently reported for the first time in a small
case–control study from Greenland [7], and it was found
that the genetic polymorphisms in CYP1A1 (Val) and
CYP17 (A1) may increase the BC risk among Inuit women,
and that the risk increases with higher serum levels of
PFOS and PFOA [27].
We now report results from a much larger study within a
well-defined cohort, namely the Danish National Birth
Cohort (DNBC). We estimate the association between
concentrations of PFAS determined during pregnancy, and
the risk of BC during a follow-up period of 10–15 years
postpartum.
Methods
Study design and population
The study was designed as a case-cohort study nested
within the Danish National Birth Cohort (DNBC), which
was established from 1996 to 2002 and include about
100,000 pregnancies. About half of all pregnant women in
Denmark in this time period were invited by their general
practitioners (GPs) to take part in the study and about 60 %
accepted this invitation.
Questionnaires on lifestyle and environmental exposure
(including diet, height, weight, diseases in the family,
smoking, and alcohol intake) were administered by a
computer-administered interview (CAT) by trained female
interviewers twice during pregnancy and 6 months post-
partum [28, 29]. All questionnaires are available in an
English translation at www.DNBC.dk. Blood was drawn
from the mother in the first and second trimester during
pregnancy and from the umbilical cord taken shortly after
birth and stored at -80 C. The DNBC participant was
followed up to 2010 in this study.
For the present study, all 250 women diagnosed with
breast cancer after recruitment according to the cancer
registry (BC) and 233 controls (frequency matched on age
and parity; taken at random from the entire cohort at
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baseline) were selected for further PFAS analyses. The
information on the BC diagnosis was taken from the
National Patient Registry [30]. Neither the sample size nor
previous findings justified sub-classification of BC. In our
sampling, the BC cases were classified as given by their
ICD codes (DC500, 500B, 501, 502, 503, 504, 505, 508,
and 509). Blood was drawn between the 6th and 14th
gestation weeks for analyses of PFAS.
PFAS measurements
Ten perfluorocarboxylated acids (PFCAs, C5–C14): per-
fluoro-n-pentanoic acid (PFPeA), perfluorohexanoic acid
(PFHxA), perfluoroheptanoic acid (PFHpA), PFOA, per-
fluorononanoic acid (PFNA), perfluorodecanoic acid
(PFDA), perfluoroundecanoic acid (PFUnA), perfluorodo-
decanoic acid (PFDoA), perfluorotridecanoic acid
(PFTrA), perfluorotetradecanoic acid (PFTeA); five per-
fluoroalkyl-sulfonates [PFSAs, C4–C10: perfluorobutane
sulfonate (PFBS), perfluorohexane sulfonate (PFHxS),
perfluoroheptane sulfonate (PFHpS), PFOS and perfluo-
rodecane sulfonate (PFDS)] and one sulfonamide (per-
flurooctane-sulfonamide, PFOSA), were determined at the
Department of Environmental Science, Aarhus University.
The extraction method was based on solid phase extraction
(SPE) as described by Keller et al. [31]. Before extraction,









and 13C4-PFOS). Instrumental analysis was performed by
liquid chromatography–tandem mass spectrometry (LC–
MS–MS) with electrospray ionization (ESI) in negative
mode. The samples were extracted and analyzed in batches
together with a procedural blank and two control samples,
represented by an aliquot of test material previously ana-
lyzed in a ring test and for which assigned values for PFOS
and PFOA concentrations are available. Detection limits
ranged from 0.02 to 0.7 ng/ml. Quality control: method
performance is regularly tested three times a year by par-
ticipating in the Arctic Monitoring and Assessment Pro-
gramme (AMAP) Ring Test for Organic Pollutants in
Human Serum organized by Institute Nationale de Sante´
Publique du Que´bec [32]. The information about the per-
formance of the method (detection limits, precision, and
bias) and the results from the ring test are given in Online
Resource Table 1S and 2S, and Figure 1S.
Statistical analysis
The PFAS concentrations were grouped into RPFSA (sum
of PFBS, PFHxS, PFHpS, PFOS, PFDS, and PFOSA) and
RPFCA (sum of PFPeA, PFHxA, PFHpA, PFOA, PFNA,
PFDA, PFUnA, PFDoA, PFTrA, and PFTeA). In addition,
analyses were performed for the single compounds detec-
ted in all samples including the five PFAS; PFOS, PFHxS,
PFOA, PFNA, and PFOSA. PFOSA was also analyzed
alone because it is chemically different from the other
PFSA, being an amide and not an acid, and because
PFOSA and other sulfonamides are precursors to the cor-
responding PFOS. For all PFAS, the detection limits were
calculated, and the exact given concentration was used if
the value was above this limit. If the value was below the
detection limit, we assigned a value given by the detection
limit divided by two.
The distribution of data was checked by Q–Q plots. The
natural logarithmic transformed variables made the distri-
bution more symmetrical and thus the analysis was per-
formed on the ln-transformed data. The PFAS levels were
analyzed as continuous variables and in a priori-decided
quintiles. The correlation of PFAS and potential con-
founders was analyzed using Pearson correlation analyses.
Potential confounders considered for this analysis included
age at blood drawing, BMI before pregnancy, total number
of gravidities, oral contraceptives (OC) use, age of men-
arche, smoking status, alcohol intake, maternal education,
and physical activity based on a priori well-established
breast cancer risk factors.
Although all the cases were eligible for being sampled
as controls at the baseline of follow-up, none were in the
sampled set of controls and since we have almost complete
follow-up, unconditional logistic regression models were
used to estimate the relative risks (RRs) and 95 % confi-
dence intervals (95 % CI). The PFAS concentrations were
included as categorical and continuous variables into the
model together with potential confounders. The change in
estimate principle [33] was used to identify potential con-
founders. However, changes in estimate of more than 5 %
were only observed for BMI and menarche age for PFNA
and BC risk. For the other PFAS, the estimate change was
\5 %. Thus, the results of RRs are given as crude and
adjusted RR by including all potential confounders men-
tioned above. Since age at cancer occurrence influence the
risk profile, RR was also estimated by stratification of
cancer patient by at onset B40 and [40.
All statistical analysis was performed using SPSS ver-
sion 17.0 (SPSS Inc. Chicago, IL, USA). The statistically
significant level was set at 5 %.
Ethical approval
The study was approved by The Danish Data Protection
Agency on the 15th of March 2011 and by The Danish
National Committee on Biomedical Research Ethics on the
24th of March 2011.
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Results
Lifestyle and reproductive characteristics of the study
population
Table 1 shows that the age at interview and blood sampling
were similar for cases and controls with a mean age of
40 at diagnosis. The controls had a slightly higher BMI
(p = 0.02). No further larger differences of the character-
istics between cases and controls were observed (Table 1).
BC and serum levels of perfluoroalkyl substances
(PFAS)
Five PFAS (PFOS, PFHxS, PFOA, PFNA, and PFOSA)
were detected in all samples while for the remaining 11
PFAS the levels were below the detection limit in
0.2–99.4 % of the samples (Online Resource Table 3S).
The data for the 16 determined PFAS, including ten
PFCAs (C5–C14), five PFSAs (C4–C10) and PFOSA were
analyzed for its association with potential confounders in
controls. Weak positive correlations were found between
some PFAS and BMI, smoking, alcohol, and maternal
education. A negative correlation was found for gravidities.
The mean serum levels for the analyzed five single
compounds were for controls as follows: PFOS (30.6 ng/ml),
PFOA (5.2 ng/ml), PFHxS (1.2 ng/ml), PFNA (0.5 ng/ml),
and PFOSA (3.5 ng/ml), respectively.
The following significant correlation coefficients were
found between PFOS versus PFOA (0.69), versus PFOSA
(0.58), versus PFNA (0.42), and PFHxS (0.15). Other
significant correlation coefficients were observed for
PFOSA versus PFOA (0.36), PFNA versus PFOA (0.46)
and versus PFHxS (0.29), and PFHxS versus PFOA (0.17).
Knowing that PFOSA is a precursor for PFOS can partly
explain their relatively high correlation coefficient,
whereas the correlation coefficient of 0.36 for PFOSA
versus PFOA might suggest common sources of exposure.
For the crude and adjusted data, a weak positive associ-
ation was found between BC risk and the continuous PFOSA
data (unadjusted RR 1.03, 95 % CI 1.00–1.07; adjusted RR
1.04, 95 % CI 0.99–1.08), whereas negative relations were
seen for PFHxS (unadjusted 0.66, 95 % CI 0.47–0.92;
adjusted RR 0.66, 95 % CI 0.47–0.94). No further significant
association between the other continuous PFAS serum data
and the RRs of the BC were observed (Table 2).
The logistic regression analyses of the quintiles [using
the 1st (lowest) quintile as the reference] showed a
Table 1 Data on breast cancer
cases and their controls
Statistics: Independent t test was
used to compare the graphical
continuous variables (age, BMI,
pregnancies, TTP, menarche
age, alcohol intake (wine and
beer), and maternal physical
activity. Pearson’s Chi-square
test was used to check the
difference between cases and
controls for OC use, smoking,
maternal education status. The
non-italics are continuous data
and italics are category
variables given in %.
Significant p values (\0.05) are
given in bold
BMI body mass index, OC oral
contraceptive use, TTP time to
pregnancy
a The age at diagnosis is given
for the cases and for the
corresponding controls it is
defined as the age for the
matched controls
Characteristics Case Control p
n Mean Min–max n Mean Min–max
Age at interview (years) 250 29.8 19–42 233 29.7 20–41 0.77
Age at blood sampling (years) 250 30.4 21–42 233 29.6 20–42 0.03
Age at diagnosis (years)a 250 40.8 31–53 233 40.3 30–52 0.82
BMI before pregnancy (kg/m2) 241 22.9 16.9–38.7 231 23.8 16.3–43.4 0.02
BMI at interview (kg/m2) 237 24.0 18.3–38.9 221 25.0 18.1–42.3 0.02
Number of gravidities 250 0.5 0–6.0 233 0.4 0–5.0 0.71
Menarche age (years) 229 13.2 9.0–19.0 217 13.3 10.0–18.0 0.23
Beer (glass/week) 226 0.1 0–2.0 217 0.1 0–2.0 0.26
Wine (glass/week) 207 0.6 0–7.0 195 0.5 0–4.0 0.36
Physical activity (h/day) 250 5.7 0–53.3 233 5.6 0–51.7 0.42
OC use (yes %) 250 24.4 % 233 24.9 % 0.90
Smoking (yes %) 250 27.6 % 233 24.0 % 0.37
TTP 219 217 0.10
Did not try to get pregnant (%) 4 1.8 % 8 3.7 %
Got pregnant immediately (%) 32 14.6 % 39 18.0 %
1–2 months (%) 37 16.9 % 42 19.4 %
3–5 months (%) 54 24.7 % 31 14.3 %
6–12 months (%) 39 17.8 % 36 16.6 %
[12 months (%) 53 24.2 % 61 28.1 %
Education 249 233 0.78
Long/medium (%) 150 62.8 % 152 65.2 %
Short (%) 82 32.8 % 67 28.8 %
Unskilled (%) 17 6.8 % 14 6.0 %
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significant elevated BC risk for PFOSA in the 5th quintile
with a RR of 1.89 (95 % CI 1.01–3.54) upon adjustment
for confounders (Table 2). For the PFHxS, a significant
negative association to BC was observed for the 4th
quintile versus 1st quintile [RR 0.38 (95 % CI 0.20–0.70)]
(Table 2). Upon stratification for age at diagnosis, the
associations for both compounds were further strengthened
(Table 3); for the continuous adjusted PFOSA data the RR
was 1.07 (95 % CI 1.00–1.14) and for PFOSA in the
highest quintile (RR 2.45, 95 % CI 1.00–6.00) among
women 40 years of age or less. For PFHxS, the significance
of the continuous data disappeared, but the risk was sig-
nificant in all quintiles but the third (RR range, 0.30–0.41).
After stratification for BC occurrence at [40 years of age,
significances disappeared (Table 3).
Recently, 72 of our breast cancer cases were withdrawn
from the current Danish National Patient Register (DNPR)
making the BC cancer status uncertain for this group. We
therefore repeated all our analyses after excluding these
cases and the following minor differences were observed.
The BMI association disappeared. In the analyses based on
continuous data, PFOSA was slightly more strongly cor-
related with BC risk (unadjusted RR 1.04, 95 % CI
1.00–1.08, adjusted RR 1.05, 95 % CI 1.00–1.09), and
again a negative correlation of PFHxS and BC risk was
found for the unadjusted data (RR 0.65, 95 % CI
0.44–0.96), whereas upon adjustment, the significant cor-
relation disappeared (RR 0.67, 95 % CI 0.45–1.01). The
logistic regression analyses of the quintiles also showed a
stronger significant correlation for PFOSA in the 5th
quintile (adjusted RR 2.40, 95 % CI 1.20–4.83). For
PFHxS, a significant negative correlation with BC risk was
observed in the 4th quintile before and after adjustment of
confounders. Upon stratification for age at diagnosis, the
positive association of PFOSA in the highest quintile and
BC risk was even stronger for the women younger or
40 years of age (adjusted RR 3.42, 95 % CI 1.25–9.36).
The negative correlation of PFHxS and BC risk was only
observed at the 2nd and 4th quintile (adjusted RR 0.3).









RR (95 % CI)
PFOS 250/233 0.99b 221/215 0.99 (0.98–1.01)b
\20.42 48/49 1.0 (ref) 42/46 1.0 (ref)
20.42–25.31 55/42 1.34 52/40 1.51 (0.81–2.71)
25.31–30.20 56/41 1.39 49/39 1.51 (0.82–2.84)
30.20–39.07 47/50 0.96 43/44 1.13 (0.59–2.04)
[39.07 44/51 0.88 35/46 0.90 (0.47–1.70)
PFOA 250/233 0.99b 221/215 1.00 (0.90–1.11)b
\3.69 51/46 1.0 (ref) 46/43 1.0 (ref)
3.69–4.59 49/49 0.90 46/48 0.97 (0.53–1.75)
4.59–5.42 50/47 0.96 43/41 1.02 (0.56–1.89)
5.42–6.53 53/42 1.14 46/40 1.14 (0.62–2.12)
[6.53 47/49 0.87 40/43 0.94 (0.51–1.76)
PFNA 250/233 1.00b 221/215 0.76 (0.30–1.94)b
\0.32 49/48 1.0 (ref) 44/41 1.0 (ref)
0.32–0.42 53/44 1.14 50/40 1.10 (0.60–2.02)
0.42–0.50 58/39 0.74 38/46 0.75 (0.41–1.40)
0.50–0.64 45/52 1.12 47/40 1.08 (0.58–1.99)
[0.64 45/50 0.78 42/48 0.80 (0.43–1.47)
PFHxS 250/233 0.66b 221/215 0.66 (0.47–0.94)b
\0.76 64/38 1.0 (ref) 58/35 1.0 (ref)
0.76–0.92 49/46 0.63 42/42 0.64 (0.34–1.18)
0.92–1.12 52/46 0.67 47/43 0.70 (0.38–1.29)
1.12–1.35 37/56 0.39 32/52 0.38 (0.20–0.70)
[1.35 48/47 0.61 42/43 0.61 (0.33–1.12)
PFOSA 250/233 1.03b 221/215 1.04 (0.99–1.08)b
\0.93 48/49 1.0 (ref) 43/47 1.0 (ref)
0.93–1.70 53/44 1.23 48/41 1.38 (0.75–2.52)
1.70–2.83 44/53 0.85 38/49 0.91 (0.49–1.66)
2.83–5.75 46/50 0.94 41/45 1.11 (0.60–2.05)
[5.75 59/37 1.63 51/33 1.89 (1.01–3.54)
sumPFSA 250/233 1.00b 221/215 1.00 (0.99–1.01)b
\24.43 52/45 1.0 (ref) 46/44 1.0 (ref)
24.43–29.58 52/46 0.96 48/42 1.19 (0.66–2.16)
29.58–35.67 53/42 1.09 38/42 1.15 (0.62–2.13)
35.67–45.38 49/48 0.88 41/41 1.09 (0.59–2.02)
[45.38 44/51 0.75 51/46 0.82 (0.43–1.55)
sumPFCA 250/233 0.99b 221/215 1.00 (0.91–1.09)b
\4.82 50/47 1.0 (ref) 45/43 1.0 (ref)
4.82–5.85 49/48 0.96 44/47 0.87 (0.48–1.59)
5.85–6.80 49/48 0.96 43/44 0.92 (0.50–1.69)
6.80–8.02 57/38 1.44 52/34 1.49 (0.80–2.77)
[8.02 44/52 0.80 37/47 0.76 (0.41–1.41)
sumPFAS 250/233 1.00b 221/215 1.00 (0.99–1.01)b
\29.54 50/46 1.0 (ref) 44/45 1.0 (ref)
29.54–35.32 53/48 1.00 50/44 1.24 (0.68–2.25)









RR (95 % CI)
42.17–53.11 45/51 0.80 40/45 0.96 (0.52–1.78)
[53.11 46/49 0.86 38/44 0.94 (0.50–1.78)
Bold data indicates significance (p \ 0.05).
a Adjusted for age at blood sampling, BMI before pregnancy, gra-
vidity, OC use, menarche age, smoking during pregnancy, alcohol
intake, maternal education and physical activity
b RR was obtained from the original continuous variables.
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Table 3 Adjusted relative risk
(RR) of breast cancer in
accordance to PFAS exposure
stratified by age at diagnosis
Adjusted for age at sampling,
BMI before pregnancy,
gravidity, OC use, menarche
age, smoking during pregnancy,
alcohol intake, maternal
education and physical activity.
Bold data indicates significance
(p \ 0.05).




Age \40 Age [40
Cases/controls RR (95 % CI) Cases/controls RR (95 % CI)
PFOS 132/120 0.99 (0.97–1.02)a 118/113 1.00 (0.98–1.02)a
\20.42 26/22 1.00 (ref) 22/27 1.00 (ref)
20.42–25.31 28/23 1.22 (0.52–2.88) 27/19 2.30 (0.94–5.64)
25.31–30.20 30/20 1.38 (0.58–3.30) 26/21 1.90 (0.73–4.97)
30.20–39.07 22/30 0.79 (0.33–1.88) 25/20 2.22 (0.87–5.69)
[39.07 26/25 1.01 (0.41–2.50) 18/26 0.88 (0.33–2.38)
PFOA 132/120 0.99 (0.84–1.18)a 118/113 1.01 (0.88–1.16)a
\3.69 26/19 1.00 (ref) 25/27 1.00 (ref)
3.69–4.59 24/31 0.66 (0.28–1.55) 25/18 1.77 (0.73–4.31)
4.59–5.42 29/19 1.26 (0.51–3.15) 21/28 0.93 (0.38–2.27)
5.42–6.53 28/25 0.83 (0.35–1.99) 25/17 1.91 (0.76–4.83)
[6.53 25/26 0.77 (0.31–1.91) 22/23 1.17 (0.48–2.86)
PFNA 132/120 0.54 (0.13–2.32)a 118/113 1.09 (0.30–3.96)a
\0.32 29/19 1.00 (ref) 20/24 1.00 (ref)
0.32–0.42 33/22 1.05 (0.44–2.50) 24/22 1.19 (0.48–2.96)
0.42–0.50 21/27 0.52 (0.22–1.26) 22/24 1.30 (0.52–3.25)
0.50–0.64 28/28 0.82 (0.35–1.88) 27/15 1.85 (0.70–4.86)
[0.64 21/24 0.56 (0.23–1.37) 25/28 1.14 (0.46–2.82)
PFHxS 132/120 0.64 (0.39–1.05)a 118/113 0.71 (0.43–1.15)a
\0.76 40/19 1.00 (ref) 24/19 1.00 (ref)
0.76–0.92 29/29 0.39 (0.17–0.88) 20/17 1.23 (0.44–3.42)
0.92–1.12 23/21 0.56 (0.23–1.35) 29/25 1.04 (0.40–2.68)
1.12–1.35 19/26 0.30 (0.12–0.72) 18/30 0.52 (0.20–1.35)
[1.35 21/25 0.41 (0.17–0.96) 27/22 1.01 (0.40–2.54)
PFOSA 132/120 1.07 (1.00–1.14)a 118/113 1.01 (0.97–1.07)a
\0.93 29/33 1.00 (ref) 19/16 1.00 (ref)
0.93–1.70 32/27 1.53 (0.70–3.32) 21/17 1.30 (0.48–3.56)
1.70–2.83 22/24 1.04 (0.45–2.40) 22/29 0.96 (0.37–2.51)
2.83–5.75 22/24 1.10 (0.46–2.59) 24/26 1.37 (0.52–3.61)
[5.75 27/12 2.45 (1.00–6.00) 32/25 1.62 (0.61–4.29)
sumPFSA 132/120 1.00 (0.98–1.02)a 118/113 1.00 (0.98–1.02)a
\24.43 31/23 1.00 (ref) 21/22 1.00 (ref)
24.43–29.58 28/26 0.90 (0.40–2.03) 24/21 2.00 (0.67–5.28)
29.58–35.67 24/18 1.06 (0.44–2.52) 29/24 1.81 (0.38–3.84)
35.67–45.38 23/30 0.62 (0.27–1.44) 26/18 2.62 (0.44–5.19)
[45.38 26/23 1.01 (0.42–2.40) 18/28 0.79 (0.29–2.14)
sumPFCA 132/120 0.99 (0.85–1.15)a 118/113 1.00 (0.89–1.14)a
\4.82 26/23 1.00 (ref) 24/24 1.00 (ref)
4.82–5.85 27/23 1.04 (0.44–2.46) 22/25 0.98 (0.39–2.40)
5.85–6.80 27/27 0.90 (0.38–2.12) 22/21 1.25 (0.49–3.22)
6.80–8.02 30/20 1.37 (0.57–3.27) 28/18 1.73 (0.69–4.34)
[8.02 22/27 0.68 (0.28–1.65) 22/25 1.01 (0.40–2.51)
sumPFAS 132/120 1.00 (0.99–1.02)a 118/113 1.00 (0.99–1.02)a
\29.54 29/24 1.00 (ref) 21/22 1.00 (ref)
29.54–35.32 31/25 1.22 (0.54–2.78) 22/24 1.67 (0.66–4.21)
35.32–42.17 23/16 1.09 (0.44–2.69) 33/21 2.50 (0.96–6.52)
42.17–53.11 22/32 0.64 (0.27–1.49) 23/20 2.09 (0.78–5.61)
[53.11 27/23 1.17 (0.49–2.79) 19/26 0.94 (0.34–2.56)
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Among women older than 40 years of age, no significant
correlation with BC risk was observed for any of the PFAS
congeners. In addition, the levels of PFOSA in cases were
significantly higher than the controls (p = 0.04).
Discussion and conclusions
The results of this study suggest no strong or coherent asso-
ciation between BC occurrence and the measured PFAS
concentrations in plasma taken up to 15 years before the
diagnosis of breast cancer. The PFOSA association was weak
for the continuous data and statistical significance was
restricted to the highest exposure level with no support by the
estimate for trends. The few positive association could be
chance findings related to multiple testing. However, sensi-
tivity analyses excluding 72 cases recently withdrawn from
the DNPR resulted in stronger associations between PFOSA
and RR of BC and weaker for the PFHxS data. Moreover, it
should be noted that a similar association with PFOSA serum
levels was found in our previous study on breast cancer in
Greenlandic women [7]. In contrast to the present study, the
study on BC in Greenlandic women was based on the PFAS
serum levels taken at the time of diagnosis and included also
post-menopausal older women (median age 50–54 vs. this
study 30 years at blood drawing) [7].
We studied BC risk using prospectively collected BC
data in predominately premenopausal women. We have
exposure data from early in pregnancy, which probably
covers the exposure status for a time period that at least
overlaps with the causal time window of interest. Our study
has a size that leaves room for some statistical uncertainty,
as indicated by the wide confidence limits, but if there is a
linear dose–response association, the trend test would
probably pick it up. There are some limitations of this
study related to the degree of heterogeneity of the cases,
which may have compromised the power of the study if the
exposure is only causal for subtypes of BC. We do not have
information on case characteristics regarding, i.e., tumor
size, nodal status, in situ versus invasive, and immune
histochemical markers, i.e. ER, PR, or HER2/neu nor the
family history of breast cancer. The blood was drawn
between the 6th and 14th gestation week at the GPs at their
antenatal care regular visit. Our analyses show rather stable
PFAS values over gestational time, and the results are
adjusted for gestation age of blood drawing.
For the Greenlandic BC women, the PFOA, PFOS,
PFOSA, and PFHxS serum levels were significantly higher
in cases and showed a significantly elevated risk for BC
according to adjusted data for PFOS [OR 1.03 (1.00;
1.07)], PFOSA [OR 6.13 (1.12–33.64)], and PFHxS [OR
1.40 (0.95–2.05)] ([7], the latter two compounds OR
unpublished). In comparison, the PFOS mean levels were
slightly higher in Inuit controls than in Danish controls
(38.5 vs. 30.6 ng/ml). For PFOSA, the serum mean level
was nine times higher in Danish controls than Inuit con-
trols, 3.5 versus 0.4 ng/ml, respectively, and the mean
PFHxS serum levels were almost 2.3 times higher in Inuit
controls compared to Danish controls, 2.8 versus 1.2 ng/ml,
respectively.
It is important to note that data for both PFOSA and
PFHxS levels correlate with BC risk in both Inuit and
Danish women, although negatively for PFHxS in Danish
women. Reverse causation may account for the findings
seen in the study from Greenland but this problem is
unlikely in the Danish data.
PFOSA is a synthetic fluorocarbon compound used to
repel grease and water in food packing along with other
consumer applications [34]. It breaks down to PFOS [35].
In addition, PFOSA is a metabolic by-product of N-alkyl-
ated sulphonamides and N-methyl sulphonamidoethnanol
primarily used on carpets and textiles [36]. Moreover,
PFOSA is thought to be the biological active form of the
insecticide sulfluramid by inducing mitochondrial dys-
function [37]. Biomonitoring studies have found PFOSA in
livers of wildlife at higher parts per billion and human
serum at lower part per billion levels [38–41]. In whole
blood (WB), the concentration of PFOSA is about five
times higher than in plasma/serum (PLS). Levels up to
19.7–22.9 ng/ml in WB have been reported [42] but the
general WB/PLS level was found to be in the range of
3–4.1/0.10–0.6 ng/ml [43–45]. Because of the relatively
low level found in WB and unequal distribution to PLS, it
makes it uncertain to quantify PFOSA in plasma or serum
only. Therefore both media should be measured to assess
the real PFOSA blood concentration in future studies.
PFOSA was reported to be a potent mitochondrial toxicant
[37] and precursor of PFOS, found in human tissues. In
addition, PFOSA was the most toxic perfluorinated com-
pound in a study on developmental neurotoxicity of PFAS
using the neural transforms cell line PC12 [46].
PFHxS is found in a variety of industrial, consumer, and
dietary sources including house dust [47]. In our recent BC
study in Inuit, the PFHxS [7] was found to be a potential
BC risk factor, whereas in the present study a negative
correlation with BC risk was found. However, it should be
taken into consideration that the PFHxS serum levels were
2.3 and 4 times higher in Inuit controls and cases,
respectively, compared to DK controls and cases, respec-
tively. In addition to the possible differences in exposures
to PFHxS between Inuit and Danish women, the timing
according to case status should also be considered. If the
disease moves perfluorinated compounds to the blood-
stream, the risk estimate is biased towards higher values.
No health effects of PFHxS have yet been documented,
however PFHxS (C6) share many of the common physical
Cancer Causes Control (2014) 25:1439–1448 1445
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and chemical properties with PFOS (C8), suggesting that
PFHxS may also have biological effects similar to PFOS.
To our knowledge, no carcinogenicity in relation to PFHxS
has previously been reported, but neonatal exposure to
PFHxS was reported to cause behavioral and cognitive
disturbance in adult mice [48], being similar to observa-
tions following PFOS exposure [49]. Moreover, epidemi-
ological studies have reported a positive association
between serum levels of PFHxS and attention deficiency/
hyperactivity disorder (ADHD) and increased impulsivity
in children [50, 51].
Although perfluorooctanesulfonyl fluoride-based chem-
istry was phased out by 3M in the USA during 2000–2002,
the production is continuing and being increased in China
[52].
PFAS have been associated with effects being of
potential relevance for risk of BC such as (1) hormone
disruption in vitro [53–56], (2) genotoxic potentials in vitro
[57–60], (3) tumor promoting in rodents including reduc-
tion in mammary differentiation and increase in mammary
fibroadenomas [21, 25, 26], (4) BC risk factor in Inuit
women [7], and (5) immunosuppressive effects in humans
[61, 62]. These observations need to be further scrutinized
in studies on cellular, toxicological mechanisms involved
in vivo/ex vivo using exposure of single compounds as
well as mixtures reflecting the actual complex mixtures
found in human serum.
In conclusion, this study does not document PFAS as
overall causes of BC in Danish premenopausal women but
does not rule out that such an association may exist and
more studies are needed.
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